Michael Lillestol, MD
Internal Medicine · Fargo, NDNPI 1669427688
Payments from drug & device makers
What this record shows
The money is spread across several categories — travel and lodging (46.3%), consulting fees and food and beverage — rather than concentrated in one kind of arrangement. 30 manufacturers reported payments, led by Pfizer at 39.2% of the total. Reporting peaked in 2021 at $5,770 and has fallen 96.8% since, to $186 in 2025. Among internal medicine clinicians in ND with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 154 payments — averaging $119.99 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Pfizer$7K
- Merck$4K
- Eli Lilly$4K
- AstraZeneca$3K
- AbbVie$51
- Novo Nordisk$51
- plus $491 from 24 others
Across 3,192 payments — averaging $7085.33 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Eli Lilly$9M
- Pfizer$5.5M
- Novartis$2.5M
- AstraZeneca$1.6M
- Amgen$1.3M
- Modernatx, Inc.$832K
- plus $1.9M from 18 others
What the payments were for
- Consulting fees$7,15039%
- Travel & lodging$8,56246%
- Food & beverage$2,73515%
- Education$120%
- Gifts$200%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Pfizer | 17 | $7,236 |
| Merck | 27 | $4,255 |
| Eli Lilly | 55 | $3,677 |
| AstraZeneca | 17 | $2,718 |
| AbbVie | 3 | $51 |
| Novo Nordisk | 4 | $51 |
| Abbott | 3 | $47 |
| Boston Scientific | 2 | $36 |
| Lexicon Pharmaceuticals, Inc. | 2 | $31 |
| E.r. Squibb & Sons, L.L.C. | 2 | $29 |
| GSK | 2 | $27 |
| Pacira Therapeutics, Inc. | 1 | $26 |
| Astellas Pharma US Inc | 1 | $25 |
| Philips North America LLC | 1 | $23 |
| Madrigal Pharmaceuticals | 1 | $21 |
| Regeneron Healthcare Solutions, Inc. | 1 | $20 |
| Acadia Pharmaceuticals Inc | 1 | $20 |
| Baxter Healthcare | 1 | $18 |
| Vanda Pharmaceuticals Inc. | 1 | $17 |
| Organogenesis Inc. | 1 | $17 |
| Amarin Pharma, Inc. | 1 | $15 |
| Bayer | 1 | $14 |
| Exact Sciences | 1 | $14 |
| Actelion Pharmaceuticals US, Inc. | 1 | $14 |
| Esperion Therapeutics, Inc. | 1 | $14 |
| Otsuka America Pharmaceutical, Inc. | 1 | $14 |
| Idorsia Pharmaceuticals US Inc | 1 | $13 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $12 |
| Phathom Pharmaceuticals, Inc. | 1 | $12 |
| Sanofi-aventis U.S. LLC | 1 | $11 |
How this compares
$18,479 in reported general payments places this provider in the 95th percentile of 159 internal medicine providers in North Dakota.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 106 | $138,628 |
| EliquisApixaban | 71 | $56,133 |
| XareltoRivaroxaban | 39 | $29,299 |
| JardianceEmpagliflozin | 31 | $25,866 |
| MounjaroTirzepatide | 21 | $25,540 |
| ProliaDenosumab | 14 | $23,835 |
| EntrestoSacubitril/Valsartan | 29 | $17,830 |
| Repatha SureclickEvolocumab | 16 | $11,030 |
| Ezetimibe | 165 | $4,610 |
| Rosuvastatin Calcium | 314 | $3,830 |
| Metoprolol Succinate | 118 | $2,808 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 19 | $2,700 |
| Arnuity ElliptaFluticasone Furoate | 12 | $2,507 |
| Atorvastatin Calcium | 191 | $2,186 |
| Losartan Potassium | 198 | $2,128 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $51 | $138,628106 claims |
| PfizerEliquis | $7,236 | $56,13371 claims |
| GSKArnuity Ellipta | $27 | $2,50712 claims |
| AbbVieSynthroid | $51 | $1,54716 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 159 internal medicine providers in North Dakota.
Other internal medicine in Fargo
- Brent HellaFargo$3K
- Tricia LangloisFargo$2K
- Mark YoheFargo$2K
- Dalton PeasleeFargo$2K
- Anya de LeeuwFargo$1K
- Anastasia SchroederFargo$1K
- Mathew GervingFargo$1K
- Aselo LayawenFargo$1K
- Guillermo EstradaFargo$1K
- Sai Anil Kumar SriramojuFargo$604
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.